FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus...
Gespeichert in:
| Veröffentlicht in: | Microorganisms (Basel) 2020-04, Vol.8 (4), p.599, Article 599 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 599 |
| container_title | Microorganisms (Basel) |
| container_volume | 8 |
| creator | Stefanik, Michal Valdes, James J. Ezebuo, Fortunatus C. Haviernik, Jan Uzochukwu, Ikemefuna C. Fojtikova, Martina Salat, Jiri Eyer, Ludek Ruzek, Daniel |
| description | Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors. |
| doi_str_mv | 10.3390/microorganisms8040599 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3390_microorganisms8040599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aeee10316a554a17882b166a2eaec000</doaj_id><sourcerecordid>2394876783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c543t-2482413fc36de891d42288337686b1f7824275684e12175fdb675ac4853700863</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEotXSnwDyEYkG_BF_5IK0SruwUhESKlwtx5lsXWXtYCdbwa_H2y2rVuKAL_bYz7z2vOOieE3we8Zq_GHrbAwhbox3aZsUrjCv62fFKcVSlFRg-fzR-qQ4S-kW51ETpjh5WZwwyqggpD4t4upiWS7HMYYddOgizpuELnuzcxH873N07cZo_D48R8ZnwCTTzjlEa3_jWjehbzAOzprJBY9Cj77Mw-TGAdBqyFkZnBMk5Dz6ATGgBoYhvSpe9GZIcPYwL4rvq8vr5nN59fXTullelZZXbCpppWhFWG-Z6EDVpKsoVYoxKZRoSS_zKZVcqAoIJZL3XSskN7ZSnEmMlWCLYn3Q7YK51WN0WxN_6WCcvt_I9mkTJ2cH0AYACGZEGM4rQ6RStCVCGAoGbDYua308aI1zu4XOgp-iGZ6IPj3x7kZvwk7L7DSp9wJvHwRi-DlDmvTWJZvtMB7CnDRldaWkkLnARcEPaO5xShH64zUE63379T_bn_PePH7jMetvszPw7gDcQRv6ZB14C0csl8kZ4ySrYUJVptX_042b7r9AE2Y_sT84ztAr</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2394876783</pqid></control><display><type>article</type><title>FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Stefanik, Michal ; Valdes, James J. ; Ezebuo, Fortunatus C. ; Haviernik, Jan ; Uzochukwu, Ikemefuna C. ; Fojtikova, Martina ; Salat, Jiri ; Eyer, Ludek ; Ruzek, Daniel</creator><creatorcontrib>Stefanik, Michal ; Valdes, James J. ; Ezebuo, Fortunatus C. ; Haviernik, Jan ; Uzochukwu, Ikemefuna C. ; Fojtikova, Martina ; Salat, Jiri ; Eyer, Ludek ; Ruzek, Daniel</creatorcontrib><description>Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.</description><identifier>ISSN: 2076-2607</identifier><identifier>EISSN: 2076-2607</identifier><identifier>DOI: 10.3390/microorganisms8040599</identifier><identifier>PMID: 32326119</identifier><language>eng</language><publisher>BASEL: Mdpi</publisher><subject>antiviral ; FDA ; flavivirus ; Life Sciences & Biomedicine ; Microbiology ; Science & Technology ; tick-borne encephalitis virus ; West Nile virus ; Zika virus</subject><ispartof>Microorganisms (Basel), 2020-04, Vol.8 (4), p.599, Article 599</ispartof><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>16</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000533510400128</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c543t-2482413fc36de891d42288337686b1f7824275684e12175fdb675ac4853700863</citedby><cites>FETCH-LOGICAL-c543t-2482413fc36de891d42288337686b1f7824275684e12175fdb675ac4853700863</cites><orcidid>0000-0001-7761-0702 ; 0000-0003-4390-7780 ; 0000-0002-0237-8061 ; 0000-0001-9376-957X ; 0000-0002-2832-1215 ; 0000-0002-5139-1537 ; 0000-0003-4655-2380</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232190/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232190/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27929,27930,28253,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32326119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stefanik, Michal</creatorcontrib><creatorcontrib>Valdes, James J.</creatorcontrib><creatorcontrib>Ezebuo, Fortunatus C.</creatorcontrib><creatorcontrib>Haviernik, Jan</creatorcontrib><creatorcontrib>Uzochukwu, Ikemefuna C.</creatorcontrib><creatorcontrib>Fojtikova, Martina</creatorcontrib><creatorcontrib>Salat, Jiri</creatorcontrib><creatorcontrib>Eyer, Ludek</creatorcontrib><creatorcontrib>Ruzek, Daniel</creatorcontrib><title>FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells</title><title>Microorganisms (Basel)</title><addtitle>MICROORGANISMS</addtitle><addtitle>Microorganisms</addtitle><description>Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.</description><subject>antiviral</subject><subject>FDA</subject><subject>flavivirus</subject><subject>Life Sciences & Biomedicine</subject><subject>Microbiology</subject><subject>Science & Technology</subject><subject>tick-borne encephalitis virus</subject><subject>West Nile virus</subject><subject>Zika virus</subject><issn>2076-2607</issn><issn>2076-2607</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>DOA</sourceid><recordid>eNqNkk1v1DAQhiMEotXSnwDyEYkG_BF_5IK0SruwUhESKlwtx5lsXWXtYCdbwa_H2y2rVuKAL_bYz7z2vOOieE3we8Zq_GHrbAwhbox3aZsUrjCv62fFKcVSlFRg-fzR-qQ4S-kW51ETpjh5WZwwyqggpD4t4upiWS7HMYYddOgizpuELnuzcxH873N07cZo_D48R8ZnwCTTzjlEa3_jWjehbzAOzprJBY9Cj77Mw-TGAdBqyFkZnBMk5Dz6ATGgBoYhvSpe9GZIcPYwL4rvq8vr5nN59fXTullelZZXbCpppWhFWG-Z6EDVpKsoVYoxKZRoSS_zKZVcqAoIJZL3XSskN7ZSnEmMlWCLYn3Q7YK51WN0WxN_6WCcvt_I9mkTJ2cH0AYACGZEGM4rQ6RStCVCGAoGbDYua308aI1zu4XOgp-iGZ6IPj3x7kZvwk7L7DSp9wJvHwRi-DlDmvTWJZvtMB7CnDRldaWkkLnARcEPaO5xShH64zUE63379T_bn_PePH7jMetvszPw7gDcQRv6ZB14C0csl8kZ4ySrYUJVptX_042b7r9AE2Y_sT84ztAr</recordid><startdate>20200420</startdate><enddate>20200420</enddate><creator>Stefanik, Michal</creator><creator>Valdes, James J.</creator><creator>Ezebuo, Fortunatus C.</creator><creator>Haviernik, Jan</creator><creator>Uzochukwu, Ikemefuna C.</creator><creator>Fojtikova, Martina</creator><creator>Salat, Jiri</creator><creator>Eyer, Ludek</creator><creator>Ruzek, Daniel</creator><general>Mdpi</general><general>MDPI</general><general>MDPI AG</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7761-0702</orcidid><orcidid>https://orcid.org/0000-0003-4390-7780</orcidid><orcidid>https://orcid.org/0000-0002-0237-8061</orcidid><orcidid>https://orcid.org/0000-0001-9376-957X</orcidid><orcidid>https://orcid.org/0000-0002-2832-1215</orcidid><orcidid>https://orcid.org/0000-0002-5139-1537</orcidid><orcidid>https://orcid.org/0000-0003-4655-2380</orcidid></search><sort><creationdate>20200420</creationdate><title>FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells</title><author>Stefanik, Michal ; Valdes, James J. ; Ezebuo, Fortunatus C. ; Haviernik, Jan ; Uzochukwu, Ikemefuna C. ; Fojtikova, Martina ; Salat, Jiri ; Eyer, Ludek ; Ruzek, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c543t-2482413fc36de891d42288337686b1f7824275684e12175fdb675ac4853700863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>antiviral</topic><topic>FDA</topic><topic>flavivirus</topic><topic>Life Sciences & Biomedicine</topic><topic>Microbiology</topic><topic>Science & Technology</topic><topic>tick-borne encephalitis virus</topic><topic>West Nile virus</topic><topic>Zika virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stefanik, Michal</creatorcontrib><creatorcontrib>Valdes, James J.</creatorcontrib><creatorcontrib>Ezebuo, Fortunatus C.</creatorcontrib><creatorcontrib>Haviernik, Jan</creatorcontrib><creatorcontrib>Uzochukwu, Ikemefuna C.</creatorcontrib><creatorcontrib>Fojtikova, Martina</creatorcontrib><creatorcontrib>Salat, Jiri</creatorcontrib><creatorcontrib>Eyer, Ludek</creatorcontrib><creatorcontrib>Ruzek, Daniel</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Microorganisms (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stefanik, Michal</au><au>Valdes, James J.</au><au>Ezebuo, Fortunatus C.</au><au>Haviernik, Jan</au><au>Uzochukwu, Ikemefuna C.</au><au>Fojtikova, Martina</au><au>Salat, Jiri</au><au>Eyer, Ludek</au><au>Ruzek, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells</atitle><jtitle>Microorganisms (Basel)</jtitle><stitle>MICROORGANISMS</stitle><addtitle>Microorganisms</addtitle><date>2020-04-20</date><risdate>2020</risdate><volume>8</volume><issue>4</issue><spage>599</spage><pages>599-</pages><artnum>599</artnum><issn>2076-2607</issn><eissn>2076-2607</eissn><abstract>Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.</abstract><cop>BASEL</cop><pub>Mdpi</pub><pmid>32326119</pmid><doi>10.3390/microorganisms8040599</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-7761-0702</orcidid><orcidid>https://orcid.org/0000-0003-4390-7780</orcidid><orcidid>https://orcid.org/0000-0002-0237-8061</orcidid><orcidid>https://orcid.org/0000-0001-9376-957X</orcidid><orcidid>https://orcid.org/0000-0002-2832-1215</orcidid><orcidid>https://orcid.org/0000-0002-5139-1537</orcidid><orcidid>https://orcid.org/0000-0003-4655-2380</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2076-2607 |
| ispartof | Microorganisms (Basel), 2020-04, Vol.8 (4), p.599, Article 599 |
| issn | 2076-2607 2076-2607 |
| language | eng |
| recordid | cdi_crossref_primary_10_3390_microorganisms8040599 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | antiviral FDA flavivirus Life Sciences & Biomedicine Microbiology Science & Technology tick-borne encephalitis virus West Nile virus Zika virus |
| title | FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T23%3A58%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FDA-Approved%20Drugs%20Efavirenz,%20Tipranavir,%20and%20Dasabuvir%20Inhibit%20Replication%20of%20Multiple%20Flaviviruses%20in%20Vero%20Cells&rft.jtitle=Microorganisms%20(Basel)&rft.au=Stefanik,%20Michal&rft.date=2020-04-20&rft.volume=8&rft.issue=4&rft.spage=599&rft.pages=599-&rft.artnum=599&rft.issn=2076-2607&rft.eissn=2076-2607&rft_id=info:doi/10.3390/microorganisms8040599&rft_dat=%3Cproquest_cross%3E2394876783%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2394876783&rft_id=info:pmid/32326119&rft_doaj_id=oai_doaj_org_article_aeee10316a554a17882b166a2eaec000&rfr_iscdi=true |